Literature DB >> 34695644

Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study.

Kavya K Kannan1, Paz Vellanki2, Scott Isom3, Bernard Tawfik1, Allison Winter1, Heidi D Klepin1, Leslie R Ellis1, Rupali Roy Bhave1, Dianna Howard1, Megan Manuel1, Sarah Dralle1, Susan Lyerly1, Bayard L Powell1, Timothy S Pardee4.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34695644      PMCID： PMC8961745          DOI： 10.1016/j.leukres.2021.106731

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  12 in total

1.  Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience.

Authors:  Peter Schellongowski; Thomas Staudinger; Michael Kundi; Klaus Laczika; Gottfried J Locker; Andja Bojic; Oliver Robak; Valentin Fuhrmann; Ulrich Jäger; Peter Valent; Wolfgang R Sperr
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

2.  Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.

Authors:  Masamitsu Yanada; Gautam Borthakur; Farhad Ravandi; Carlos Bueso-Ramos; Hagop Kantarjian; Elihu Estey
Journal:  Haematologica       Date:  2008-06-02       Impact factor: 9.941

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

4.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

Authors:  M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

Review 5.  New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia.

Authors:  Ryan J Mattison; Selina M Luger; Hillard M Lazarus
Journal:  Curr Opin Hematol       Date:  2013-03       Impact factor: 3.284

6.  The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.

Authors:  Zhijian Xiao; Hua Xue; Rui Li; Li Zhang; Minghua Yu; Yushu Hao
Journal:  Am J Hematol       Date:  2008-03       Impact factor: 10.047

7.  Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.

Authors:  Tod A Morris; Carlos M DeCastro; Louis F Diehl; Jon P Gockerman; Anand S Lagoo; Zhiguo Li; Joseph O Moore; David A Rizzieri; Arati V Rao
Journal:  Leuk Res       Date:  2012-10-07       Impact factor: 3.156

8.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

9.  Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

Authors:  Wolfgang Kern; Torsten Haferlach; Claudia Schoch; Helmut Loffler; Winfried Gassmann; Achim Heinecke; Maria Christina Sauerland; Wolfgang Berdel; Thomas Buchner; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

10.  Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.

Authors:  Kebede Hussein; Balkrishna Jahagirdar; Pankaj Gupta; Linda Burns; Karen Larsen; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2008-06       Impact factor: 10.047
View more
  1 in total

1.  Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis.

Authors:  Linzhang Li; Chengwu Han; Xueying Yu; Jun Shen; Yongtong Cao
Journal:  J Healthc Eng       Date:  2022-01-25       Impact factor: 2.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.